Literature DB >> 30116941

Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis.

Satoshi Hosoki1, Masahito Takagi2, Hiroshi Yamagami3, Daisuke Ando1, Kazunori Toyoda1, Masatoshi Koga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30116941     DOI： 10.1007/s00415-018-9011-8

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

Review 1.  Idarucizumab: The Antidote for Reversal of Dabigatran.

Authors:  John W Eikelboom; Daniel J Quinlan; Joanne van Ryn; Jeffrey I Weitz
Journal:  Circulation       Date:  2015-12-22       Impact factor: 29.690

2.  Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

Authors:  E Touzé; Y Gruel; I Gouin-Thibault; E De Maistre; S Susen; P Sie; L Derex
Journal:  Eur J Neurol       Date:  2018-03-09       Impact factor: 6.089

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study.

Authors:  E M Antman; T L Wenger; V P Butler; E Haber; T W Smith
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

5.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321

6.  Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.

Authors:  Masahiro Yasaka; Ippei Ikushima; Akiko Harada; Susumu Imazu; Atsushi Taniguchi; Stephen Norris; Dietmar Gansser; Joachim Stangier; Michael Schmohl; Paul A Reilly
Journal:  Res Pract Thromb Haemost       Date:  2017-08-05
  6 in total
  3 in total

1.  Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society.

Authors:  Kazunori Toyoda; Masatoshi Koga; Yasuyuki Iguchi; Ryo Itabashi; Manabu Inoue; Yasushi Okada; Kuniaki Ogasawara; Akira Tsujino; Yasuhiro Hasegawa; Taketo Hatano; Hiroshi Yamagami; Toru Iwama; Yoshiaki Shiokawa; Yasuo Terayama; Kazuo Minematsu
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-12-05       Impact factor: 1.742

2.  Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Authors:  Mathias Ströhle; Christopher Rugg; Stefan Schmid; Dietmar Fries; Elgar Oswald
Journal:  Trauma Case Rep       Date:  2021-02-10

3.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.